Entries by admin

,

Drug Repurposing Screening Identifies Spironolactone as Potentially Effective Drug to Treat Symptoms of Schizophrenia

Schizophrenia is a complex human disease, caused both by individual genetic variation and lifestyle. Genome-wide association studies have implicated many molecular targets and biological pathways with this disease. One these pathways associated with schizophrenia is the so-called Neuregulin1 (Nrg1)-ERBB4 signaling pathway. Nrg1 is the ligand for the ERBB4, which is a membrane-spanning receptor, and therefore […]

27th July 2017 /0 Comments/by

License agreement with Boehringer Ingelheim

12th July 2017 – Munich Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH(BI) entered a non-exclusive license agreement for cell-based splitSENSOR assays providing BI with the options to screen for selected target activities relevant to schizophrenia.Systasy’s proprietary splitSENSOR assays are applied to assess activities and specificities of drug-able targets, such as receptor tyrosine kinases and […]

12th July 2017 by

Patent transfer of Double Switch Technology from Sygnis AG

May 12, 2014 – Munich Germany Systasy Bioscience GmbH and Sygnis AG closed a patent transfer deal today. A patent transfer agreement for Double Switch technology was signed. Systasy intends to integrate this technology within their EXTassay platformand offer a novel assay service termed as targetPROFILER. Systasy is very enthusiastic about the novel opportunities that this technology transfer […]

12th May 2014 by